PharVision Advisers’s Cohen & Steers CNS Stock Holding History

PharVision Advisers’s Portfolio CNS Stock Details CNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,254	Closed	-$267K	–	218
2025 Q4	$267K	Buy	+4,254	New	+$277K	0.14%	348
2025 Q3	–	Sell	-3,586	Closed	-$270K	–	677
2025 Q2	$270K	Buy	+3,586	New	+$276K	0.39%	103

Other funds holding CNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CCM

Copeland Capital Management Conshohocken, Pennsylvania $4.5B AUM 18.67% 1-Year Est. Return

PharVision Advisers's CNS Position: Q1 2026 in Review

PharVision Advisers sold out of Cohen & Steers (CNS) in Q1 2026, closing a stake of 4,254 shares — an estimated $267K sold.

PharVision Advisers first reported a position in CNS in Q2 2025 and held it in 2 quarters. The position peaked at $270K in Q2 2025. 294 funds tracked by Wall St. Rank hold CNS as of Q1 2026.

PharVision Advisers reported no remaining Cohen & Steers position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 4,254 Cohen & Steers shares in Q1 2026, an estimated $267K.
PharVision Advisers first reported a position in Cohen & Steers in Q2 2025 and held it in 2 quarters.
PharVision Advisers's Cohen & Steers position peaked at $270K in Q2 2025.
294 funds tracked by Wall St. Rank held Cohen & Steers as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.